Connect public, paid and private patent data with Google Patents Public Datasets

Formulations d'opioïdes à libération contrôlée

Info

Publication number
WO2012040651A2
WO2012040651A2 PCT/US2011/053132 US2011053132W WO2012040651A2 WO 2012040651 A2 WO2012040651 A2 WO 2012040651A2 US 2011053132 W US2011053132 W US 2011053132W WO 2012040651 A2 WO2012040651 A2 WO 2012040651A2
Authority
WO
Grant status
Application
Patent type
Prior art keywords
release
formulation
ml
ng
opioid
Prior art date
Application number
PCT/US2011/053132
Other languages
English (en)
Other versions
WO2012040651A3 (fr )
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Joseph Berry
Felix De La Iglesia
Original Assignee
QRxPharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Abstract

La présente invention concerne des formulations pharmaceutiques contenant des composants opioïdes qui possèdent chacun un profil de libération. Ces composants peuvent procurer une libération immédiate ou contrôlée de l'opioïde. L'invention a également trait à des procédés de régulation de la libération d'un ou de plusieurs composés opioïdes et à des méthodes de traitement de la douleur.
PCT/US2011/053132 2010-02-09 2011-09-23 Formulations d'opioïdes à libération contrôlée WO2012040651A3 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US38622710 true 2010-09-24 2010-09-24
US61/386,227 2010-09-24
US13/024,319 2011-02-09
US13024319 US20110195989A1 (en) 2010-02-09 2011-02-09 Controlled Release Formulations of Opioids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN 201180056278 CN103476403A (zh) 2010-09-24 2011-09-23 阿片样物质的控释制剂
CA 2812570 CA2812570A1 (fr) 2010-09-24 2011-09-23 Formulations d'opioides a liberation controlee
EP20110764653 EP2618820A2 (fr) 2010-09-24 2011-09-23 Formulations d'opioïdes à libération contrôlée
JP2013530379A JP2013537915A5 (fr) 2011-09-23

Publications (2)

Publication Number Publication Date
WO2012040651A2 true true WO2012040651A2 (fr) 2012-03-29
WO2012040651A3 true WO2012040651A3 (fr) 2012-05-18

Family

ID=44741728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053132 WO2012040651A3 (fr) 2010-02-09 2011-09-23 Formulations d'opioïdes à libération contrôlée

Country Status (4)

Country Link
CN (1) CN103476403A (fr)
CA (1) CA2812570A1 (fr)
EP (1) EP2618820A2 (fr)
WO (1) WO2012040651A3 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013153451A3 (fr) * 2012-04-09 2014-01-23 QRxPharma Ltd. Formulations d'opioïdes à libération contrôlée
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9707179B2 (en) 2001-09-21 2017-07-18 Egalet Ltd. Opioid polymer release system
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073396A1 (fr) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Conjugues analgesiques
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CA2464528A1 (fr) * 2001-11-02 2003-05-15 Elan Corporation, Plc Composition pharmaceutique
CA2599386A1 (fr) * 2005-03-28 2006-10-05 Orexo Ab Nouvelles compositions pharmaceutiques utiles dans le traitement de la douleur
US20100284960A1 (en) * 2006-11-07 2010-11-11 Nektar Therapeutics Al, Corporation Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist
WO2009143209A1 (fr) * 2008-05-20 2009-11-26 Qrxpharma Limited Thérapie contre la douleur utilisant deux opioïdes
US20110195989A1 (en) * 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073396A1 (fr) 2005-01-05 2006-07-13 Regents Of The University Of Minnesota Conjugues analgesiques
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9707179B2 (en) 2001-09-21 2017-07-18 Egalet Ltd. Opioid polymer release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
WO2013153451A3 (fr) * 2012-04-09 2014-01-23 QRxPharma Ltd. Formulations d'opioïdes à libération contrôlée
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release

Also Published As

Publication number Publication date Type
CA2812570A1 (fr) 2012-03-29 application
CN103476403A (zh) 2013-12-25 application
JP2013537915A (ja) 2013-10-07 application
WO2012040651A3 (fr) 2012-05-18 application
EP2618820A2 (fr) 2013-07-31 application

Similar Documents

Publication Publication Date Title
US7682633B2 (en) Pharmaceutical composition
US7943174B2 (en) Controlled release hydrocodone formulations
US6599529B1 (en) Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
US20100152221A1 (en) Pharmaceutical composition
US20040024006A1 (en) Opioid pharmaceutical compositions
US20030073714A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
US20100172989A1 (en) Abuse resistant melt extruded formulation having reduced alcohol interaction
US20030190358A1 (en) Sustained release hydromorphone formulations exhibiting bimodal characteristics
US20060039970A1 (en) Tamper-resistant oral opioid agonist formulations
US20100015222A1 (en) Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20090175937A1 (en) Misuse Preventative, Controlled Release Formulation
US20060073102A1 (en) Abuse-resistant opioid solid dosage form
US20120321716A1 (en) Technology for preventing abuse of solid dosage forms
US8846090B2 (en) Matrix for sustained, invariant and independent release of active compounds
US6159501A (en) Modified release multiple-units dosage composition for release of opioid compounds
US20040176402A1 (en) Controlled-release compositions containing opioid agonist and antagonist
US20040110781A1 (en) Pharmaceutical compositions containing indistinguishable drug components
US20080233156A1 (en) Pharmaceutical compositions
US20040224020A1 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US8486449B2 (en) Misuse preventative, controlled release formulation
US20110229526A1 (en) Formulations of nonopioid and confined opioid analgesics
US20090011016A1 (en) Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
WO1995014460A1 (fr) Formulations d'opioides pour le traitement de la douleur
WO2004026283A1 (fr) Sous-unite de sequestration et compositions et procedes associes
WO2010078486A2 (fr) Compositions pharmaceutiques orales contenant un opioïde et procédés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11764653

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: 2013530379

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2812570

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

REEP

Ref document number: 2011764653

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2011305161

Country of ref document: AU

Date of ref document: 20110923

Kind code of ref document: A